LOBE.CNLobe Sciences Ltd.
Nov 25, 2026 — FY 2026 Earnings & Liquidity Update
Chart by TradingViewThe schedule
- Wed25Nov
FY 2026 Earnings release focusing on cash reserves against the $0.06 to $0.12 outcome band.
- Fri15Jan
High probability of a dilutive capital raise to sustain operations, evaluating a $0.08 vs $0.04 profile.
- Thu18Feb
FQ1 2027 Earnings announcement detailing post-dilution runway, framing a $0.06 target against a $0.03 fallback.
- Tue20Apr
FDA regulatory pathway update or Phase 2 trial initiation for L-130, testing a $0.07 upside vs $0.02 downside.
- Thu27May
FQ2 2027 Earnings update on R&D expenditure and trial enrollment, targeting $0.10 or falling to $0.05.
Past
- Tue6Oct
Update on L-130 clinical progression and neurological pipeline momentum. Resolving between a jump to $0.10 or a drop to $0.05.